Ixekizumab: First Global Approval. - Wikidata - awgldk - TriplyDB

Ixekizumab: First Global Approval.

Ixekizumab: First Global Approval.

http://www.wikidata.org/entity/Q38813174

about

No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation.

P2860

Q38935474-DBA825BF-865E-4F6D-ABA2-7FB30FF8922D Q47696280-26090096-D802-43F3-A1E9-9D7F41D0A33A Q47786696-074574C4-31AE-447A-AAA8-B44D6E2CE430 Q49551961-AD5B2509-4821-4ADE-B036-3663FEA6B3F1

P2860

Ixekizumab: First Global Approval.

http://www.wikidata.org/entity/Q38813174

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Ixekizumab: First Global Approval.

@en

type

label

Ixekizumab: First Global Approval.

@en

prefLabel

Ixekizumab: First Global Approval.

@en

P1433

Q38813174-44C38454-84AE-4485-B84B-7F51C1AC87A7

P1476

Q38813174-EA3741CF-113A-410C-BAB8-67AAEB621F43

P2093

Q38813174-D1847788-BEAC-43EF-BD7E-959D2B6F0DE9

P2860

Q38813174-3CF40F26-9F92-46AB-A04A-16149F717FC0

Q38813174-69D5EAF0-CA92-4F19-B811-1F8A53D41AFB

Q38813174-84BEF5E8-3EB5-462C-9390-F36243E2E231

Q38813174-AD170F5E-F9C0-4CCD-9491-1226E69F4DBA

Q38813174-E5F1C8BE-7D03-4303-8360-A0DD52DA5414

P2888

Q38813174-412A92FE-1BB0-4EA0-B368-07CA1EC4B8A9

P304

Q38813174-83BA4416-2D96-4AF9-A3EE-A795ABE118DC

P31

Q38813174-5002EB7D-B08B-489B-BCA8-72BE83FF93A8

P356

Q38813174-3C942DDC-3FDF-4CB3-A7D6-B413041E8697

P433

Q38813174-DEF16F1C-45A9-4EE9-9D54-86BDA0551669

P478

Q38813174-BB3D495D-C172-4165-B00D-4AC2B086D313

P577

Q38813174-4E3001E2-CBFF-4E06-8528-3717DB42001D

P6179

Q38813174-6724BC67-4364-406E-88AF-65DF78F0A43E

P698

Q38813174-8969CE79-2B58-4A9D-8FB8-252147BC3394

P356

S40265-016-0579-Y

P1433

P1476

Ixekizumab: First Global Approval.

@en

P2093

Anthony Markham

http://www.w3.org/2001/XMLSchema#string

P2860

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.

Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

P2888

s40265-016-0579-y

P304

901-905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-016-0579-Y

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1005855020

http://www.w3.org/2001/XMLSchema#string

P698

27098317

http://www.w3.org/2001/XMLSchema#string